Acknowledging the Rare Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 3:30 pm - 5:00 pm CT

https://na.eventscloud.com/website/98255/ In this 90-minute symposium, some of the foremost experts in light-chain (AL) amyloidosis research and care will share actionable strategies for navigating complex challenges in this rare disease. Topics will include Diagnosis, staging, and stratifying: Improving timeliness and accuracy Treatment: Developing personalized, evidence-based plans Patient support: Helping patients navigate the long journey Workflows: Optimizing systems and teamwork The event speakers, involved in some of the most consequential trials in AL amyloidosis, will also examine key data for current treatments and novel approaches like fibril targeting. Register now to secure your spot, and prepare your questions for the live Q&A at the end of the session. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

Acknowledging the Rare Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 3:30 pm - 5:00 pm CT

https://na.eventscloud.com/website/98255/ This live, case-based symposium is designed to help healthcare professionals interpret and apply clinically relevant evidence to individualized treatment decisions for persons with hemophilia. The program will focus on persistent disease and treatment burden despite improved outcomes, the need to evaluate treatment success beyond bleeding rates, and the importance of tailoring care to patient-specific factors that drive burden across subgroups, including emerging data on nonfactor replacement prophylaxis options. Through expert-led discussion of real-world cases and audience polling, participants will examine how the expanding availability of novel prophylactic options—including factor replacement therapies, factor VIIIa mimetics, rebalancing agents, and gene therapies—offer new strategies for optimizing not only bleed rates but long-term joint health, treatment burden, and quality of life for people with hemophilia. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

Viewpoint: ‘Sanitation and nutrition not vaccines’: The rejectionists’ latest false substitute for staying up to date on your shots Jess Steier | November 12, 2026

https://geneticliteracyproject.org/2026/11/12/viewpoint-sanitation-and-nutrition-not-vaccines-the-rejectionists-latest-false-substitute-for-staying-up-to-date-on-your-shots/ Has anyone ever heard matzoh ball soup referred to as Jewish penicillin? I’ve called it that my whole life. It was the first thing my mom made whenever I was sick, a pot chock full of veggies, herbs, and protein (and the matzoh balls!). It was good for my body and good for my soul, a warm generational hug in a bowl. Of course, we know soup isn’t actually penicillin, which is an antibiotic (and I was usually eating it for a cold or the flu, which are caused by viruses that antibiotics can’t treat anyway). That soup nourished me and comforted me while my body fought off whatever I had, but it couldn’t keep me from catching the next bug going around school.

Clonal haematopoiesis: a major link in the cancer–Alzheimer's disease inverse correlation eBioMedicine (+...)

Clonal haematopoiesis: a major link in the cancer–Alzheimer's disease inverse correlation eBioMedicine https://www.thelancet.com/journals/ebiom/issue/vol133nonull/PIIS2352-3964(26)X2009-6 First characterised in 2014, clonal haematopoiesis is a condition defined by the expansion of a haematopoietic stem cell clone, and its progeny, carrying somatic mutations in leukaemia-associated genes. Sensitive sequencing techniques show that clonal haematopoiesis, irrespective of clone size, becomes near-universal with ageing. A related term, clonal haematopoiesis of indeterminate potential (CHIP), describes the presence of a clone that has expanded to a variant allele fraction of ≥2% (and as a result ≥4% of nucleated blood cells) and is considered clinically significant. As expected, CHIP is a strong risk factor for subsequent haematologic cancers (hazard ratio 12·9 [95% CI 5·8–28·7]). Incident coronary heart disease (2·0 [1·2–3·4]), ischaemic stroke (2·6 [1·4–4·8]), and all-cause mortality (1·4 [1·1–1·8]) also increased. Mechanistic studies in animal models suggest that altered gene expression and changes in the function of circulating mutant macrophages are likely to contribute to the more rapid expansion of atherosclerotic lesions in the presence of CHIP.

Move over BMI: new obesity definition is better for predicting your health A fresh approach considers waist circumference, rather than just weight and height, providing a more accurate classification. By Mariana Lenharo

Move over BMI: new obesity definition is better for predicting your health A fresh approach considers waist circumference, rather than just weight and height, providing a more accurate classification. By Mariana Lenharo https://www.nature.com/articles/d41586-026-03636-5 Clinicians have debated for years whether body mass index (BMI) — a metric derived from a person’s height and weight — is the best way to define and diagnose obesity. Now, an approach that measures waist circumference and focuses more closely on excess body fat has proved to be better than BMI at predicting a person’s risk of death.

RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus Vaccines and monoclonal antibody injections are cutting hospitalizations for the respiratory virus. By Liam Drew

RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus Vaccines and monoclonal antibody injections are cutting hospitalizations for the respiratory virus. By Liam Drew https://www.nature.com/articles/d41586-026-03573-3 “Something’s wrong with the data. There are too few people in hospitals” with respiratory syncytial virus (RSV), epidemiologist Caroline Klint Johannesen recalls a colleague remarking while analysing Danish health records for last winter.

New culprit in early Alzheimer’s: Blood–brain barrier blocks protective proteins The brain relies on crucial proteins to maintain neurons. This system is disrupted in mice with neurological disease. By Mohana Basu

New culprit in early Alzheimer’s: Blood–brain barrier blocks protective proteins The brain relies on crucial proteins to maintain neurons. This system is disrupted in mice with neurological disease. By Mohana Basu For decades, scientists thought of the blood–brain barrier as an impenetrable layer. Overtime that view has changed, as researchers realized the barrier was more permeable than first thought. Now a team have catalogued almost 100 proteins that can pass through it to maintain brain health.1 https://www.nature.com/articles/d41586-026-03655-2?utm_source=Live+Audience&utm_campaign=21e610d5d7-nature-briefing-daily-20261111&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Brain-protein highway clogs in Alzheimer’s Researchers have catalogued almost 100 proteins that get a free pass through the blood–brain barrier to maintain the health of neurons. Most of these proteins were produced in distant organs, particularly the liver. The team found that the transport of some of these proteins is disrupted in mice with a brain disease that mimics early-stage Alzheimer’s disease. The work suggests that the brain actively imports the proteins it needs to stay healthy, and that the breakdown of that transport drives the dysfunction seen in neurodegenerative disease, says neuroscientist and study co-author Andrew Yang.